Alloplex Biotherapeutics, Inc. announced that it has received funding from new investors Daewoong pharmaceutical Co.,Ltd. and Hanall Biopharma Co.,Ltd on August 19, 2021.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
31,550 KRW | -14.50% | -11.87% | -28.78% |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-28.78% | 1.16B | |
+40.73% | 739B | |
+32.04% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.13% | 240B | |
+9.60% | 210B | |
-4.91% | 206B | |
+6.17% | 164B |
- Stock Market
- Equities
- A009420 Stock
- News Hanall Biopharma Co., Ltd.
- Alloplex Biotherapeutics, Inc. announced that it has received $1 million in funding from Daewoong pharmaceutical Co.,Ltd, Hanall Biopharma Co.,Ltd